Specialty
Cataract & Refractive Dermatology General Ophthalmology Glaucoma Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Login

Retina’s Believe It Or Not!

By: Caroline R. Baumal, MD; Peter Kaiser, MD; Dante J. Pieramici, MD; John D. Pitcher, III, MD; Sunil Srivastava, MD

Webinar Credits: 1.5

Expiration Date: Wednesday, October 31, 2018
Release Date: May, 2017

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Discuss a wide variety of treatment approaches for numerous vitreoretinal disease states
  • Compare the most recent monotherapy and combination therapy clinical study evidence using available therapies for AMD, DME, and RVO
  • Develop individualized treatment plans for patients with retina disorders that use a combination of imaging, treat and extend, or treat and observe
  • Apply case study examples to real world clinical settings

Accreditation and Designation Statement

Accreditation Statement
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement
Evolve Medical Education LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

The following faculty members have the following financial relationships with commercial interests:

Caroline R. Baumal, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau:  Genentech, Inc and Stealth BioTherapeutics.

Peter Kaiser, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau:  Aerpio Therapeutics; Alcon; Allergan Inc.; Allegro Ophthalmics; Bayer Corporation;  Biogen, Inc.; Novartis, Ohr Pharmaceutical, Inc.; Ophthotech Corporation; Regeneron Pharmaceuticals, Inc.; Sanfen Pharmaceutical Company; Shire Plc.; and ThromboGenics NV.

Dante J. Pieramici, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau:  Allergan, Inc.; Bayer Corporation and Genentech, Inc.

John D. Pitcher, III, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau:  Allergan, Inc.; Genentech, Inc. and Regeneron Pharmaceuticals, Inc.

Sunil Srivasta, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Santen Pharmaceutical Co, Ltd. Grant/Research Support: Allergan, Inc.

Nathan C. Steinle, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau:  Alimera Sciences, Inc.; Genentech, Inc. Notal Vision, Inc.; and Vortex Surgical. Grant/Research Support: Carl Zeiss Meditec, Inc.; Genentech, Inc. and Regeneron Pharmaceuticals, Inc.

Editorial Support Disclosure

Michelle Dalton, Writer and Cheryl Cavanaugh, MS, Evolve Medical Education LLC have no real or apparent conflicts of interest to report.

Rishi P. Singh, MD, Peer Reviewer,  has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau:  Alcon; Allergan  Inc.; Carl Zeiss Meditec; Genentech, Inc; Optos; Regeneron Pharmaceuticals, Inc; and Shire Plc. Grant/Research Support: Alcon; Apellis Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC,  Regeneron Pharmaceuticals, Inc. or Carl Zeiss Meditec, Inc.

Video Resources

Part one

Part two

Part three

Part four

Part five

Part six

Part seven

Part eight

Next

Test

Instructions

  • DisagreeNeutralAgree
  • DisagreeNeutralAgree
  • DisagreeNeutralAgree
  • DisagreeNeutralAgree
  • YesNo
    The design of the program was effective for the content conveyed
    The content supported the identified learnng objectives
    The content was free of commercial bias
    The ccontent was relative to your practice
    The faculty was effective
    You were satisfied overall with the activity
    Would you recommend this program to your colleagues?
Back